Literature DB >> 1370174

Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects.

C A Boucher1, E O'Sullivan, J W Mulder, C Ramautarsing, P Kellam, G Darby, J M Lange, J Goudsmit, B A Larder.   

Abstract

The order of appearance in the reverse transcriptase gene of four mutations implicated in the development of resistance to zidovudine was investigated by selective polymerase chain reaction. Serial human immunodeficiency virus isolates were studied from 18 initially asymptomatic individuals who had been treated with zidovudine for 2 years. Most subjects had similar patterns. The first mutation occurred transiently at codon 70; its disappearance was paralleled by the appearance of a mutation at codon 215. Subsequently, in some individuals, the mutation at codon 70 reappeared. During the 2 years of treatment, no mutations developed at codon 219 and only one at codon 67, suggesting that most individuals developed only partly resistant virus. This was confirmed by plaque-reduction assay. Six subjects progressed to AIDS within the 2-year study period, confirming that the development of highly resistant isolates is not required for progression in treated individuals. No clear temporal relationship was found between the development of partial resistance and progression.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370174     DOI: 10.1093/infdis/165.1.105

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  109 in total

Review 1.  A fossil record of zidovudine resistance in transmitted isolates of HIV-1.

Authors:  D R Kuritzkes
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

2.  Genetic drift and within-host metapopulation dynamics of HIV-1 infection.

Authors:  S D Frost; M J Dumaurier; S Wain-Hobson; A J Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-29       Impact factor: 11.205

3.  Molecular evidence of HIV-1 transmission in a criminal case.

Authors:  Michael L Metzker; David P Mindell; Xiao-Mei Liu; Roger G Ptak; Richard A Gibbs; David M Hillis
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-18       Impact factor: 11.205

4.  Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitors.

Authors:  B Masquelier; E Race; C Tamalet; D Descamps; J Izopet; C Buffet-Janvresse; A Ruffault; A S Mohammed; J Cottalorda; A Schmuck; V Calvez; E Dam; H Fleury; F Brun-Vézinet
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

5.  Zidovudine as modern day salvage therapy for HIV infection.

Authors:  Katherine E Kupiec; James W Johnson; Luis F Barroso; Rebekah H Wrenn; John C Williamson
Journal:  AIDS Patient Care STDS       Date:  2014-11       Impact factor: 5.078

6.  Antiretroviral Drug Resistance in HIV-1.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

7.  Molecular basis of adaptive convergence in experimental populations of RNA viruses.

Authors:  José M Cuevas; Santiago F Elena; Andrés Moya
Journal:  Genetics       Date:  2002-10       Impact factor: 4.562

8.  Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy.

Authors:  Rami Kantor; Robert W Shafer; Stephen Follansbee; Jonathan Taylor; David Shilane; Leo Hurley; Dong-Phuong Nguyen; David Katzenstein; W Jeffrey Fessel
Journal:  AIDS       Date:  2004-07-23       Impact factor: 4.177

9.  Feline immunodeficiency virus infection: plasma, but not peripheral blood mononuclear cell virus titer is influenced by zidovudine and cyclosporine.

Authors:  J Meers; G M del Fierro; R B Cope; H S Park; W K Greene; W F Robinson
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

Review 10.  Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

Authors:  E Sandström; B Oberg
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.